Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa
Date
2017
Type:
Artículo
item.page.extent
44
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Clinical Infectious Diseases, Volume 65, Issue 1, 1 July 2017, Pages 158–161
Keywords
ceftolozane, carbapenem resistant, P. aeruginosa, multidrug resistant